APO Research
Talk to an analyst

APO RESEARCH · REPORT

HPV Therapeutic Vaccines

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global HPV Therapeutic Vaccines Market Analysis and Forecast 2026-2032

22 December 2025190 pages

Choose your research edition.

Industry ResearchHPV Therapeutic Vaccines Industry Research Report 2026115 pages · $2,950 USDIndustry Growth & TrendsGlobal HPV Therapeutic Vaccines Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal HPV Therapeutic Vaccines Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal HPV Therapeutic Vaccines Market Outlook and Growth Opportunities 2026198 pages · $4,250 USDMarket Analysis & ForecastGlobal HPV Therapeutic Vaccines Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global HPV Therapeutic Vaccines market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for HPV Therapeutic Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for HPV Therapeutic Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for HPV Therapeutic Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for HPV Therapeutic Vaccines is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of HPV Therapeutic Vaccines include Shanghai Bovax Biotechnology Co., Ltd., Sanofi Pasteur, Johnson and Johnson., Pfizer, GlaxoSmithKline plc, Wantai BioPharm, Serum Institute, Profectus BioSciences, Inc. and Merck & Co., Inc, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for HPV Therapeutic Vaccines, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of HPV Therapeutic Vaccines, also provides the revenue of main regions and countries. Of the upcoming market potential for HPV Therapeutic Vaccines, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the HPV Therapeutic Vaccines revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global HPV Therapeutic Vaccines market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for HPV Therapeutic Vaccines revenue, projected growth trends, production technology, application and end-user industry.

HPV Therapeutic Vaccines Segment by Company

Shanghai Bovax Biotechnology Co., Ltd.

Sanofi Pasteur

Johnson and Johnson.

Pfizer

GlaxoSmithKline plc

Wantai BioPharm

Serum Institute

Profectus BioSciences, Inc.

Merck & Co., Inc

ISA Pharmaceuticals

INOVIO Pharmaceuticals

Emergent BioSolutions

Astellas Pharma

2A Pharma AB

HPV Therapeutic Vaccines Segment by Type

Bivalent HPV vaccine

Quadrivalent HPV vaccine

HPV Therapeutic Vaccines Segment by Application

Man

Woman

HPV Therapeutic Vaccines Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global HPV Therapeutic Vaccines market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of HPV Therapeutic Vaccines and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of HPV Therapeutic Vaccines.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of HPV Therapeutic Vaccines in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of HPV Therapeutic Vaccines company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, HPV Therapeutic Vaccines revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global HPV Therapeutic Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Bivalent HPV vaccine Major Player Table 3. Quadrivalent HPV vaccine Major Player Table 4. Global HPV Therapeutic Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Man Major Player Table 6. Woman Major Player Table 7. HPV Therapeutic Vaccines Industry Trends Table 8. HPV Therapeutic Vaccines Industry Drivers Table 9. HPV Therapeutic Vaccines Industry Opportunities and Challenges Table 10. HPV Therapeutic Vaccines Industry Restraints Table 11. Global HPV Therapeutic Vaccines Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 12. Global HPV Therapeutic Vaccines Market Size by Region (2021-2026) & (US$ Million) Table 13. Global HPV Therapeutic Vaccines Market Share by Region (2021-2026) Table 14. Global HPV Therapeutic Vaccines Market Size by Region (2027-2032) & (US$ Million) Table 15. Global HPV Therapeutic Vaccines Market Share by Region (2027-2032) Table 16. Global HPV Therapeutic Vaccines Revenue by Players (US$ Million) & (2021-2026) Table 17. Global HPV Therapeutic Vaccines Revenue Market Share by Players (2021-2026) Table 18. Global HPV Therapeutic Vaccines Key Players Ranking, 2024 VS 2025 VS 2026 Table 19. Global HPV Therapeutic Vaccines Key Players Headquarters & Area Served Table 20. Global HPV Therapeutic Vaccines Players, Product Type & Application Table 21. Global HPV Therapeutic Vaccines Players Establishment Date Table 22. Global Players Market Concentration Ratio (CR5 and HHI) Table 23. Global HPV Therapeutic Vaccines by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 24. Global HPV Therapeutic Vaccines Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 26. Global HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 27. Global HPV Therapeutic Vaccines Revenue Market Share by Type (2021-2026) Table 28. Global HPV Therapeutic Vaccines Revenue Market Share by Type (2027-2032) Table 29. Global HPV Therapeutic Vaccines Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 31. Global HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 32. Global HPV Therapeutic Vaccines Revenue Market Share by Application (2021-2026) Table 33. Global HPV Therapeutic Vaccines Revenue Market Share by Application (2027-2032) Table 34. Shanghai Bovax Biotechnology Co., Ltd. Company Information Table 35. Shanghai Bovax Biotechnology Co., Ltd. Business Overview Table 36. Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 37. Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Product Portfolio Table 38. Shanghai Bovax Biotechnology Co., Ltd. Recent Development Table 39. Sanofi Pasteur Company Information Table 40. Sanofi Pasteur Business Overview Table 41. Sanofi Pasteur HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 42. Sanofi Pasteur HPV Therapeutic Vaccines Product Portfolio Table 43. Sanofi Pasteur Recent Development Table 44. Johnson and Johnson. Company Information Table 45. Johnson and Johnson. Business Overview Table 46. Johnson and Johnson. HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 47. Johnson and Johnson. HPV Therapeutic Vaccines Product Portfolio Table 48. Johnson and Johnson. Recent Development Table 49. Pfizer Company Information Table 50. Pfizer Business Overview Table 51. Pfizer HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 52. Pfizer HPV Therapeutic Vaccines Product Portfolio Table 53. Pfizer Recent Development Table 54. GlaxoSmithKline plc Company Information Table 55. GlaxoSmithKline plc Business Overview Table 56. GlaxoSmithKline plc HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 57. GlaxoSmithKline plc HPV Therapeutic Vaccines Product Portfolio Table 58. GlaxoSmithKline plc Recent Development Table 59. Wantai BioPharm Company Information Table 60. Wantai BioPharm Business Overview Table 61. Wantai BioPharm HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 62. Wantai BioPharm HPV Therapeutic Vaccines Product Portfolio Table 63. Wantai BioPharm Recent Development Table 64. Serum Institute Company Information Table 65. Serum Institute Business Overview Table 66. Serum Institute HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 67. Serum Institute HPV Therapeutic Vaccines Product Portfolio Table 68. Serum Institute Recent Development Table 69. Profectus BioSciences, Inc. Company Information Table 70. Profectus BioSciences, Inc. Business Overview Table 71. Profectus BioSciences, Inc. HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 72. Profectus BioSciences, Inc. HPV Therapeutic Vaccines Product Portfolio Table 73. Profectus BioSciences, Inc. Recent Development Table 74. Merck & Co., Inc Company Information Table 75. Merck & Co., Inc Business Overview Table 76. Merck & Co., Inc HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 77. Merck & Co., Inc HPV Therapeutic Vaccines Product Portfolio Table 78. Merck & Co., Inc Recent Development Table 79. ISA Pharmaceuticals Company Information Table 80. ISA Pharmaceuticals Business Overview Table 81. ISA Pharmaceuticals HPV Therapeutic Vaccines Revenue and Gross Margin (US$ Million) & (2021-2026) Table 82. ISA Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio Table 83. ISA Pharmaceuticals Recent Development Table 84. INOVIO Pharmaceuticals Company Information Table 85. INOVIO Pharmaceuticals Business Overview Table 86. INOVIO Pharmaceuticals HPV Therapeutic Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 87. INOVIO Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio Table 88. INOVIO Pharmaceuticals Recent Development Table 89. Emergent BioSolutions Company Information Table 90. Emergent BioSolutions Business Overview Table 91. Emergent BioSolutions HPV Therapeutic Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Emergent BioSolutions HPV Therapeutic Vaccines Product Portfolio Table 93. Emergent BioSolutions Recent Development Table 94. Astellas Pharma Company Information Table 95. Astellas Pharma Business Overview Table 96. Astellas Pharma HPV Therapeutic Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Astellas Pharma HPV Therapeutic Vaccines Product Portfolio Table 98. Astellas Pharma Recent Development Table 99. 2A Pharma AB Company Information Table 100. 2A Pharma AB Business Overview Table 101. 2A Pharma AB HPV Therapeutic Vaccines Sales (k units), Revenue (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. 2A Pharma AB HPV Therapeutic Vaccines Product Portfolio Table 103. 2A Pharma AB Recent Development Table 104. North America HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 105. North America HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 106. North America HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 107. North America HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 108. North America HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 109. North America HPV Therapeutic Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 110. North America HPV Therapeutic Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 111. Europe HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 112. Europe HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 113. Europe HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 114. Europe HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 115. Europe HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 116. Europe HPV Therapeutic Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 117. Europe HPV Therapeutic Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 118. China HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 119. China HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 120. China HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 121. China HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 122. Asia HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 123. Asia HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 124. Asia HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 125. Asia HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 126. Asia HPV Therapeutic Vaccines Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 127. Asia HPV Therapeutic Vaccines Revenue by Region (US$ Million) & (2021-2026) Table 128. Asia HPV Therapeutic Vaccines Revenue by Region (US$ Million) & (2027-2032) Table 129. SAMEA HPV Therapeutic Vaccines Revenue by Type (2021-2026) & (US$ Million) Table 130. SAMEA HPV Therapeutic Vaccines Revenue by Type (2027-2032) & (US$ Million) Table 131. SAMEA HPV Therapeutic Vaccines Revenue by Application (2021-2026) & (US$ Million) Table 132. SAMEA HPV Therapeutic Vaccines Revenue by Application (2027-2032) & (US$ Million) Table 133. SAMEA HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 134. SAMEA HPV Therapeutic Vaccines Revenue by Country (2021-2026) & (US$ Million) Table 135. SAMEA HPV Therapeutic Vaccines Revenue by Country (US$ Million) & (2027-2032) Table 136. Research Programs/Design for This Report Table 137. Authors List of This Report Table 138. Secondary Sources Table 139. Primary Sources List of Figures Figure 1. HPV Therapeutic Vaccines Image Figure 2. Global HPV Therapeutic Vaccines Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global HPV Therapeutic Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 4. Bivalent HPV vaccine Image Figure 5. Quadrivalent HPV vaccine Image Figure 6. Global HPV Therapeutic Vaccines Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global HPV Therapeutic Vaccines Market Size Share 2021 VS 2025 VS 2032 Figure 8. Man Image Figure 9. Woman Image Figure 10. Global HPV Therapeutic Vaccines Market Size (US$ Million) & (2021-2032) Figure 11. Global HPV Therapeutic Vaccines Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 12. Global HPV Therapeutic Vaccines Market Share by Region: 2021 VS 2025 VS 2032 Figure 13. Global HPV Therapeutic Vaccines Players Revenue Share Top 10 and Top 5 in 2025 Figure 14. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 15. Global HPV Therapeutic Vaccines Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global HPV Therapeutic Vaccines Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global HPV Therapeutic Vaccines Revenue Market Share by Type (2021-2032) Figure 18. Global HPV Therapeutic Vaccines Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 19. Global HPV Therapeutic Vaccines Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 20. Global HPV Therapeutic Vaccines Revenue Market Share by Application (2021-2032) Figure 21. North America HPV Therapeutic Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 22. North America HPV Therapeutic Vaccines Revenue Share by Type (2021-2032) Figure 23. North America HPV Therapeutic Vaccines Revenue Share by Application (2021-2032) Figure 24. North America HPV Therapeutic Vaccines Revenue Share by Country (2021-2032) Figure 25. United States HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 26. Canada HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Mexico HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Europe HPV Therapeutic Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 29. Europe HPV Therapeutic Vaccines Revenue Share by Type (2021-2032) Figure 30. Europe HPV Therapeutic Vaccines Revenue Share by Application (2021-2032) Figure 31. Europe HPV Therapeutic Vaccines Revenue Share by Country (2021-2032) Figure 32. Germany HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 33. France HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. U.K. HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. Italy HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Spain HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Russia HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Netherlands HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Nordic Countries HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. China HPV Therapeutic Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 41. China HPV Therapeutic Vaccines Revenue Share by Type (2021-2032) Figure 42. China HPV Therapeutic Vaccines Revenue Share by Application (2021-2032) Figure 43. Asia HPV Therapeutic Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 44. Asia HPV Therapeutic Vaccines Revenue Share by Type (2021-2032) Figure 45. Asia HPV Therapeutic Vaccines Revenue Share by Application (2021-2032) Figure 46. Asia HPV Therapeutic Vaccines Revenue Share by Region (2021-2032) Figure 47. Japan HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 48. South Korea HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. India HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. Australia HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Taiwan HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Southeast Asia HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. SAMEA HPV Therapeutic Vaccines Revenue YoY Growth (2021-2032) & (US$ Million) Figure 54. SAMEA HPV Therapeutic Vaccines Revenue Share by Type (2021-2032) Figure 55. SAMEA HPV Therapeutic Vaccines Revenue Share by Application (2021-2032) Figure 56. SAMEA HPV Therapeutic Vaccines Revenue Share by Country (2021-2032) Figure 57. Brazil HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 58. Argentina HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Chile HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Colombia HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Peru HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Saudi Arabia HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Israel HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. UAE HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. Turkey HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Iran HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Egypt HPV Therapeutic Vaccines Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Years Considered Figure 69. Research Process Figure 70. Key Executives Interviewed

Scope & coverage.

Types
  • Bivalent HPV vaccine
  • Quadrivalent HPV vaccine
Applications
  • Man
  • Woman
Companies covered
  • Shanghai Bovax Biotechnology Co., Ltd.
  • Sanofi Pasteur
  • Johnson and Johnson.
  • Pfizer
  • GlaxoSmithKline plc
  • Wantai BioPharm
  • Serum Institute
  • Profectus BioSciences, Inc.
  • Merck & Co., Inc
  • ISA Pharmaceuticals
  • INOVIO Pharmaceuticals
  • Emergent BioSolutions
  • Astellas Pharma
  • 2A Pharma AB

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 HPV Therapeutic Vaccines Market by Type
  3. 1.2.1 Global HPV Therapeutic Vaccines Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Bivalent HPV vaccine
  5. 1.2.3 Quadrivalent HPV vaccine
  6. 1.3 HPV Therapeutic Vaccines Market by Application
  7. 1.3.1 Global HPV Therapeutic Vaccines Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Man
  9. 1.3.3 Woman
  10. 1.4 Assumptions and Limitations
  11. 1.5 Study Goals and Objectives
2 HPV Therapeutic Vaccines Market Dynamics
  1. 2.1 HPV Therapeutic Vaccines Industry Trends
  2. 2.2 HPV Therapeutic Vaccines Industry Drivers
  3. 2.3 HPV Therapeutic Vaccines Industry Opportunities and Challenges
  4. 2.4 HPV Therapeutic Vaccines Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global HPV Therapeutic Vaccines Market Perspective (2021-2032)
  2. 3.2 Global HPV Therapeutic Vaccines Growth Trends by Region
  3. 3.2.1 Global HPV Therapeutic Vaccines Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global HPV Therapeutic Vaccines Market Size by Region (2021-2026)
  5. 3.2.3 Global HPV Therapeutic Vaccines Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global HPV Therapeutic Vaccines Revenue by Players
  2. 4.1.1 Global HPV Therapeutic Vaccines Revenue by Players (2021-2026)
  3. 4.1.2 Global HPV Therapeutic Vaccines Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global HPV Therapeutic Vaccines Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global HPV Therapeutic Vaccines Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global HPV Therapeutic Vaccines Key Players Headquarters & Area Served
  7. 4.4 Global HPV Therapeutic Vaccines Players, Product Type & Application
  8. 4.5 Global HPV Therapeutic Vaccines Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global HPV Therapeutic Vaccines Market CR5 and HHI
  11. 4.6.3 2025 HPV Therapeutic Vaccines Tier 1, Tier 2, and Tier 3
5 HPV Therapeutic Vaccines Market Size by Type
  1. 5.1 Global HPV Therapeutic Vaccines Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 5.3 Global HPV Therapeutic Vaccines Revenue Market Share by Type (2021-2032)
6 HPV Therapeutic Vaccines Market Size by Application
  1. 6.1 Global HPV Therapeutic Vaccines Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  3. 6.3 Global HPV Therapeutic Vaccines Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Shanghai Bovax Biotechnology Co., Ltd.
  2. 7.1.1 Shanghai Bovax Biotechnology Co., Ltd. Company Information
  3. 7.1.2 Shanghai Bovax Biotechnology Co., Ltd. Business Overview
  4. 7.1.3 Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Shanghai Bovax Biotechnology Co., Ltd. HPV Therapeutic Vaccines Product Portfolio
  6. 7.1.5 Shanghai Bovax Biotechnology Co., Ltd. Recent Developments
  7. 7.2 Sanofi Pasteur
  8. 7.2.1 Sanofi Pasteur Company Information
  9. 7.2.2 Sanofi Pasteur Business Overview
  10. 7.2.3 Sanofi Pasteur HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Sanofi Pasteur HPV Therapeutic Vaccines Product Portfolio
  12. 7.2.5 Sanofi Pasteur Recent Developments
  13. 7.3 Johnson and Johnson.
  14. 7.3.1 Johnson and Johnson. Company Information
  15. 7.3.2 Johnson and Johnson. Business Overview
  16. 7.3.3 Johnson and Johnson. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Johnson and Johnson. HPV Therapeutic Vaccines Product Portfolio
  18. 7.3.5 Johnson and Johnson. Recent Developments
  19. 7.4 Pfizer
  20. 7.4.1 Pfizer Company Information
  21. 7.4.2 Pfizer Business Overview
  22. 7.4.3 Pfizer HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Pfizer HPV Therapeutic Vaccines Product Portfolio
  24. 7.4.5 Pfizer Recent Developments
  25. 7.5 GlaxoSmithKline plc
  26. 7.5.1 GlaxoSmithKline plc Company Information
  27. 7.5.2 GlaxoSmithKline plc Business Overview
  28. 7.5.3 GlaxoSmithKline plc HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  29. 7.5.4 GlaxoSmithKline plc HPV Therapeutic Vaccines Product Portfolio
  30. 7.5.5 GlaxoSmithKline plc Recent Developments
  31. 7.6 Wantai BioPharm
  32. 7.6.1 Wantai BioPharm Company Information
  33. 7.6.2 Wantai BioPharm Business Overview
  34. 7.6.3 Wantai BioPharm HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Wantai BioPharm HPV Therapeutic Vaccines Product Portfolio
  36. 7.6.5 Wantai BioPharm Recent Developments
  37. 7.7 Serum Institute
  38. 7.7.1 Serum Institute Company Information
  39. 7.7.2 Serum Institute Business Overview
  40. 7.7.3 Serum Institute HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Serum Institute HPV Therapeutic Vaccines Product Portfolio
  42. 7.7.5 Serum Institute Recent Developments
  43. 7.8 Profectus BioSciences, Inc.
  44. 7.8.1 Profectus BioSciences, Inc. Company Information
  45. 7.8.2 Profectus BioSciences, Inc. Business Overview
  46. 7.8.3 Profectus BioSciences, Inc. HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Profectus BioSciences, Inc. HPV Therapeutic Vaccines Product Portfolio
  48. 7.8.5 Profectus BioSciences, Inc. Recent Developments
  49. 7.9 Merck & Co., Inc
  50. 7.9.1 Merck & Co., Inc Company Information
  51. 7.9.2 Merck & Co., Inc Business Overview
  52. 7.9.3 Merck & Co., Inc HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Merck & Co., Inc HPV Therapeutic Vaccines Product Portfolio
  54. 7.9.5 Merck & Co., Inc Recent Developments
  55. 7.10 ISA Pharmaceuticals
  56. 7.10.1 ISA Pharmaceuticals Company Information
  57. 7.10.2 ISA Pharmaceuticals Business Overview
  58. 7.10.3 ISA Pharmaceuticals HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  59. 7.10.4 ISA Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio
  60. 7.10.5 ISA Pharmaceuticals Recent Developments
  61. 7.11 INOVIO Pharmaceuticals
  62. 7.11.1 INOVIO Pharmaceuticals Company Information
  63. 7.11.2 INOVIO Pharmaceuticals Business Overview
  64. 7.11.3 INOVIO Pharmaceuticals HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  65. 7.11.4 INOVIO Pharmaceuticals HPV Therapeutic Vaccines Product Portfolio
  66. 7.11.5 INOVIO Pharmaceuticals Recent Developments
  67. 7.12 Emergent BioSolutions
  68. 7.12.1 Emergent BioSolutions Company Information
  69. 7.12.2 Emergent BioSolutions Business Overview
  70. 7.12.3 Emergent BioSolutions HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Emergent BioSolutions HPV Therapeutic Vaccines Product Portfolio
  72. 7.12.5 Emergent BioSolutions Recent Developments
  73. 7.13 Astellas Pharma
  74. 7.13.1 Astellas Pharma Company Information
  75. 7.13.2 Astellas Pharma Business Overview
  76. 7.13.3 Astellas Pharma HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  77. 7.13.4 Astellas Pharma HPV Therapeutic Vaccines Product Portfolio
  78. 7.13.5 Astellas Pharma Recent Developments
  79. 7.14 2A Pharma AB
  80. 7.14.1 2A Pharma AB Company Information
  81. 7.14.2 2A Pharma AB Business Overview
  82. 7.14.3 2A Pharma AB HPV Therapeutic Vaccines Revenue and Gross Margin (2021-2026)
  83. 7.14.4 2A Pharma AB HPV Therapeutic Vaccines Product Portfolio
  84. 7.14.5 2A Pharma AB Recent Developments
8 North America
  1. 8.1 North America HPV Therapeutic Vaccines Revenue (2021-2032)
  2. 8.2 North America HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 8.2.1 North America HPV Therapeutic Vaccines Revenue by Type (2021-2026)
  4. 8.2.2 North America HPV Therapeutic Vaccines Revenue by Type (2027-2032)
  5. 8.3 North America HPV Therapeutic Vaccines Revenue Share by Type (2021-2032)
  6. 8.4 North America HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  7. 8.4.1 North America HPV Therapeutic Vaccines Revenue by Application (2021-2026)
  8. 8.4.2 North America HPV Therapeutic Vaccines Revenue by Application (2027-2032)
  9. 8.5 North America HPV Therapeutic Vaccines Revenue Share by Application (2021-2032)
  10. 8.6 North America HPV Therapeutic Vaccines Revenue by Country
  11. 8.6.1 North America HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America HPV Therapeutic Vaccines Revenue by Country (2021-2026)
  13. 8.6.3 North America HPV Therapeutic Vaccines Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe HPV Therapeutic Vaccines Revenue (2021-2032)
  2. 9.2 Europe HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 9.2.1 Europe HPV Therapeutic Vaccines Revenue by Type (2021-2026)
  4. 9.2.2 Europe HPV Therapeutic Vaccines Revenue by Type (2027-2032)
  5. 9.3 Europe HPV Therapeutic Vaccines Revenue Share by Type (2021-2032)
  6. 9.4 Europe HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  7. 9.4.1 Europe HPV Therapeutic Vaccines Revenue by Application (2021-2026)
  8. 9.4.2 Europe HPV Therapeutic Vaccines Revenue by Application (2027-2032)
  9. 9.5 Europe HPV Therapeutic Vaccines Revenue Share by Application (2021-2032)
  10. 9.6 Europe HPV Therapeutic Vaccines Revenue by Country
  11. 9.6.1 Europe HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe HPV Therapeutic Vaccines Revenue by Country (2021-2026)
  13. 9.6.3 Europe HPV Therapeutic Vaccines Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China HPV Therapeutic Vaccines Revenue (2021-2032)
  2. 10.2 China HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 10.2.1 China HPV Therapeutic Vaccines Revenue by Type (2021-2026)
  4. 10.2.2 China HPV Therapeutic Vaccines Revenue by Type (2027-2032)
  5. 10.3 China HPV Therapeutic Vaccines Revenue Share by Type (2021-2032)
  6. 10.4 China HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  7. 10.4.1 China HPV Therapeutic Vaccines Revenue by Application (2021-2026)
  8. 10.4.2 China HPV Therapeutic Vaccines Revenue by Application (2027-2032)
  9. 10.5 China HPV Therapeutic Vaccines Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia HPV Therapeutic Vaccines Revenue (2021-2032)
  2. 11.2 Asia HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 11.2.1 Asia HPV Therapeutic Vaccines Revenue by Type (2021-2026)
  4. 11.2.2 Asia HPV Therapeutic Vaccines Revenue by Type (2027-2032)
  5. 11.3 Asia HPV Therapeutic Vaccines Revenue Share by Type (2021-2032)
  6. 11.4 Asia HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  7. 11.4.1 Asia HPV Therapeutic Vaccines Revenue by Application (2021-2026)
  8. 11.4.2 Asia HPV Therapeutic Vaccines Revenue by Application (2027-2032)
  9. 11.5 Asia HPV Therapeutic Vaccines Revenue Share by Application (2021-2032)
  10. 11.6 Asia HPV Therapeutic Vaccines Revenue by Country
  11. 11.6.1 Asia HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia HPV Therapeutic Vaccines Revenue by Country (2021-2026)
  13. 11.6.3 Asia HPV Therapeutic Vaccines Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA HPV Therapeutic Vaccines Revenue (2021-2032)
  2. 12.2 SAMEA HPV Therapeutic Vaccines Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA HPV Therapeutic Vaccines Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA HPV Therapeutic Vaccines Revenue by Type (2027-2032)
  5. 12.3 SAMEA HPV Therapeutic Vaccines Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA HPV Therapeutic Vaccines Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA HPV Therapeutic Vaccines Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA HPV Therapeutic Vaccines Revenue by Application (2027-2032)
  9. 12.5 SAMEA HPV Therapeutic Vaccines Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA HPV Therapeutic Vaccines Revenue by Country
  11. 12.6.1 SAMEA HPV Therapeutic Vaccines Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA HPV Therapeutic Vaccines Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA HPV Therapeutic Vaccines Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst